ClinicalTrials.gg
Not yet recruitingNCT06669169Updated Nov 1, 2024

Efficacy and Safety of Jia Shen Tablets in Chronic Heart Failure

A Phase 2 interventional study of Jia Shen Tablet Placebo and Low dose Jia Shen Tablet in Heart Failure, sponsored by Tasly Pharmaceutical Group Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
288
Allocation
Randomized
Ages
40 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 376 studies in Heart Failure with a site in China — 162 open to participants now, 183 under way, 18 of them phase 3. Heart Failure · China.

Planned enrollment
75th of 246
288 · median 127
Started
2025
with 34 others
Phase 2
22 of 376
6 open now
Primary completion
2026-12
later than 81 of 182 live
Registered
271st of 376
by date

Among the 376 studies in Heart Failure with a site in China, this one is the 75th largest by planned enrollment of the 246 interventional ones that give a count, is one of 35 that started in 2025, is one of 22 in phase 2, reaches primary completion later than 81 of the 182 other live ones, and was the 271st registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

162 of the 376 studies in Heart Failure with a site in China are open now. Recruiting first, the newest first:

157 more — sign in →

All 162 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 40 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 376 studies in Heart Failure with a site in China, or all of them as a file.
02

Study summary

Evaluate the efficacy and safety of Jia Shen Tablets in patients with Chronic Heart Failure.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
40 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-79 years, either sex;
  • Meet the diagnostic criteria for CHD and CHF;
  • Meet the TCM differentiation criteria of yang qi deficiency and blood stasis in CHF;
  • Class Ⅱ to Ⅲ for functional classification;
  • Willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • CHF with acute exacerbation or intravenous drug therapy;
  • Received cardiac resynchronization therapy (CRT) or other heart failure devices;
  • Within 3 months before randomization, acute coronary syndrome(ACS), stroke or (TIA) occurred or received cardiac revascularization (PCI, CABG);
  • Plan to undergo cardiac revascularization (PCI, CABG) or cardiac resynchronization therapy (CRT) during the trial period;
  • Severe arrhythmias [such as persistent atrial fibrillation, permanent atrial fibrillation, ventricular tachycardia, second-degree type II or higher sinus or atrioventricular block without pacemaker placement, (QTc) exceeding 480 ms after heart rate adjustment according to Fridericia's formula, or known history or symptoms of long QT syndrome];
  • Severe hypertension (systolic blood pressure ≥180mm Hg or diastolic blood pressure ≥110mm Hg) or hypotension (systolic blood pressure \< 90 mmHg);
  • Heart failure caused by other cardiovascular diseases such as congenital heart disease, severe stenosis or insufficiency of heart valves, cardiomyopathy (e.g. hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, dilated cardiomyopathy, alcoholic cardiomyopathy), moderate pericardial effusion, constrictive pericarditis, and infective endocarditis;
  • Combined with liver, kidney, hematopoietic system and other serious primary diseases, (ALT) or aspartate aminotransferase (AST) more than 3 times the upper limit of local laboratory normal value, the estimated (eGFR) \< 30 ml/min/1.73m2, Blood potassium > 5.5 mmol/L or (Hb) \< 90 g/L; Malignant tumors, severe neuroendocrine system diseases and mental diseases;
  • Pregnant or lactating;
  • Participating in other interventional clinical studies within 1 month before screening;
  • Allergic constitution, or allergic to Chinese medicines of Jia Shen Tablets (such as Periploca sepium, salvia miltiorrhiza, etc.);
  • The investigator determines that the patient is unable to complete the study or comply with the requirements of the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
288 participants (estimated)

Study arms

  • Placebo comparator
    Placebo group

    Drug: Jia Shen Tablet Placebo

  • Experimental
    Low dose group

    Drug: Low dose Jia Shen Tablet

  • Experimental
    High dose group

    Drug: High dose Jia Shen Tablet

Interventions

  • DrugJia Shen Tablet Placebo

    Jia Shen Tablet Placebo contains 4 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks

  • Low dose Jia Shen Tablet contains 2 tablets (0.47 g per tablet) and 2 placebo tablets (0.47 g per placebo tablet),take orally, 2 times a day for 12 weeks

  • High dose Jia Shen Tablet contains 4 tablets (0.47 g per tablet),take orally, 2 times a day for 12 weeks

06

What researchers measure

Primary outcomes

  1. 6-Minutes-Walking-Distance (6MWD): the change from baseline to Week 12.

    Time frame: Baseline and Week 12.

Secondary outcomes

  1. 6-Minutes-Walking-Distance (6MWD): the change from baseline to Week 6.

    Time frame: Baseline and Week 6.

  2. NT-proBNP: the change from baseline to Week 6 and 12.

    Time frame: Baseline, Week 6 and 12.

  3. NT-proBNP: the proportion of patients demonstrating a decrease in NT-proBNP level of at least 30%.

    Time frame: Baseline, Week 6 and 12.

  4. Echocardiogram: Measurements will be made of the left ventricle's end diastolic diameter (LVEDD), end diastolic volume (LVEDV), end systolic volume (LVESV), left ventricular ejection fraction(LVEF), stroke volume (SV), and cardiac output (CO).

    Time frame: Baseline and Week 12.

  5. NYHA functional classification: Measure the percentage of participants whose NYHA functional classification is improved/worsened/unchanged from baseline to Week 6 and 12.

    Time frame: Baseline, Week 6 and 12.

  6. MLHFQ Score: the change from baseline to Week 6 and 12.

    The MLHFQ consists of 21 elements representing varying degrees of impact of HF on health related quality of life. Each item in this questionnaire is scored from 0 (none) to 5 (very much), and the total item score is from 0 (none) to 105 (very much).

    Time frame: Baseline, Week 6 and 12.

  7. Traditional Chinese Medicine(TCM) Syndrome Score: change from baseline to Week 6 and 12.

    There were 3 primary symptoms and 4 secondary symptoms. The state of the tongue and pulse is used to evaluate and score TCM symptoms. The standard of TCM primary symptoms scored as without 0, light 2, medium 4, heavy 6 points. The standard of TCM secondary symptoms scored as without 0, light 1, medium 2, heavy 3 points. Tongue picture and pulse condition did not count.

    Time frame: Baseline, Week 6 and 12.

  8. Dyspnea, weakness and edema: the rate of disappearance of the symptoms (dyspnea, weakness, and edema) from baseline to Week 6 and 12.

    Time frame: Baseline, Week 6 and 12.

  9. Cardiovascular Adverse Events: Incidence of Cardiovascular AEs(cardiovascular death, hospitalization for worsening heart failure, hospitalization for nonfatal myocardial infarction, hospitalization for nonfatal stroke).

    Time frame: Week 12.

07

Study locations

1 site
  • The First Affiliated Hospital of Tianjin University of traditional Chinese
    Tianjin, Tianjin, China
    • Jingyuan Mao · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2025; primary completion for Dec 2026, 23 months later.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 23 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2024
First posted
Nov 1, 2024
StartEst.
Jan 31, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06669169
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Jan 31, 2025 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 1, 2024

Study contacts

Rui Liu
Contact
liurui2@tasly.com
022-86343626

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jiashen

Start the discussion